Currently, there are 75.45M common shares owned by the public and among those 52.99M shares have been available to trade.
The company’s stock has a 5-day price change of -11.33% and 29.55% over the past three months. TRVI shares are trading 197.76% year to date (YTD), with the 12-month market performance up to 187.05% higher. It has a 12-month low price of $1.27 and touched a high of $4.68 over the same period. TRVI has an average intraday trading volume of 1.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.55%, 26.99%, and 34.02% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Trevi Therapeutics Inc (NASDAQ: TRVI) shares accounts for 35.34% of the company’s 75.45M shares outstanding.
It has a market capitalization of $356.56M and a beta (3y monthly) value of 0.91. The earnings-per-share (ttm) stands at -$0.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.48% over the week and 9.28% over the month.
Earnings per share for the fiscal year are expected to decrease by -67.24%, and -1.65% over the next financial year.
Looking at the support for the TRVI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 12, 2024, with the firm’s price target at $6-$7.50. Leerink Partners coverage for the Trevi Therapeutics Inc (TRVI) stock in a research note released on September 09, 2024 offered a Outperform rating with a price target of $7. Raymond James was of a view on August 30, 2024 that the stock is Outperform, while H.C. Wainwright gave the stock Buy rating on August 30, 2024, issuing a price target of $6. Rodman & Renshaw on their part issued Buy rating on June 13, 2024.
